CHI3L1 and myeloid sarcoma: YKL40 represents a pathophysiological biomarker reflecting immune/inflammatory mechanisms in neurodegenerative diseases and it was found to be also increased in and/or associated with progression of patients with FTD, amyotrophic lateral sclerosis, neuromyelitis optica, and MS [73,74,75].